"臺北市立萬芳醫院委託-財團法人臺北醫學大學辦理"

During the past decade, Taipei Medical University-WanFang Hospital conducted 55 clinical trials. In the 10-year time frame, 55 clinical trials started and 12 clinical trials were completed, i.e. on average, 21.8% percent of trials that started reached the finish line to date. In the past 5 years, 31 clinical trials started and 7 clinical trials were completed. i.e. 22.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Taipei Medical University-WanFang Hospital" #1 sponsor was "Taipei Medical University WanFang Hospital" with 100 trials, followed by "Janssen Research & Development, LLC" with 6 trials sponsored, "Medigen Vaccine Biologics Corp." with 4 trials sponsored, "Taipei Medical University" with 4 trials sponsored and "Boehringer Ingelheim" with 4 trials sponsored. Other sponsors include 19 different institutions and companies that sponsored additional 25 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Taipei Medical University-WanFang Hospital" #1 collaborator was "National Science Council, Taiwan" with 3 trials as a collaborator, "AbbVie" with 1 trials as a collaborator, "Ark Biosciences Pty Ltd." with 1 trials as a collaborator, "Asian Gynecologic Oncology Group" with 1 trials as a collaborator and "Biomedical Advanced Research and Development Authority" with 1 trials as a collaborator. Other collaborators include 21 different institutions and companies that were collaborators in the rest 31 trials.

According to Clinical.Site data, the most researched conditions in "Taipei Medical University-WanFang Hospital" are "Polycystic Ovary Syndrome" (8 trials), "Schizophrenia" (6 trials), "Pregnant Women" (4 trials), "Atrial Fibrillation" (3 trials) and "Stroke" (3 trials). Many other conditions were trialed in "Taipei Medical University-WanFang Hospital" in a lesser frequency.

Most popular intervention types in "Taipei Medical University-WanFang Hospital" are "Drug" (31 trials), "Other" (18 trials), "Biological" (10 trials), "Dietary Supplement" (6 trials) and "Behavioral" (5 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (12 trials), "MVC-COV1901(S protein with adjuvant)" (2 trials), "Pimodivir 600 mg" (2 trials), "SOC Treatment" (2 trials) and "placebo" (2 trials). Other intervention names were less common.

The vast majority of trials in "Taipei Medical University-WanFang Hospital" are 118 trials for "All" genders, 17 trials for "Female" genders and 4 trials for "Male" genders.

Currently, there are NaN active trials in "Taipei Medical University-WanFang Hospital". undefined are not yet recruiting, 12 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 59 completed trials in Taipei Medical University-WanFang Hospital, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Taipei Medical University-WanFang Hospital, 4 "Phase 1" clinical trials were conducted, 14 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 5 trials, and there were also 31 trials that are defined as “Not Applicable".